In this perspective, new clinical trials recently investigated new biologics as Tezepelumab, an anti-TSLP, and its ability to reduce the annualized rate of asthma exacerbations and to greatly improve lung function compared to placebo [5]. The gene discussed is TSLP; the disease is asthma.